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Label-free quantitative LC–MS proﬁling of complex body ﬂuids has become an important analytical tool
for biomarker and biological knowledge discovery in the past decade. Accurate processing, statistical
analysis and validation of acquired data diversiﬁed by the different types of mass spectrometers, massomputational biology
uantitative data processing
tatistical analysis and validation
abel-free quantiﬁcation
iomarker discovery
omparative LC–MS proﬁling
spectrometer parameter settings and applied sample preparation steps are essential to answer complex
life science research questions and understand the molecular mechanism of disease onset and develop-
ments. This review provides insight into the main modules of label-free data processing pipelines with
statistical analysis and validation and discusses recent developments. Special emphasis is devoted to
quality control methods, performance assessment of complete workﬂows and algorithms of individual
modules. Finally, the review discusses the current state and trends in high throughput data processing
and analysis solutions for users with little bioinformatics knowledge.
© 2010 Elsevier B.V. Open access under the Elsevier OA license. . IntroductionThe recent widespread application of mass spectrometry to
uantify and identify large numbers of compounds in biological
atrices leads to an explosion of acquired data. The goals of these
easurements are to explore the underlying molecular mech-
Abbreviations: 2D-LC–MS, two dimensional liquid chromatography coupled to
ass spectrometry; AMT, accuratemass and retention time tag; APEX, absolute pro-
ein expression; APML, annotated putative peptide markup language; Cap-LC–MS,
C–MS system equipped with capillary LC column (1 mm internal diameter) and
sing ionspray for ionization; Chip LC, LC–MS system equipped with nano-LC
olumn (75m internal diameter) integrated in a microﬂuidic device and using
lectrospray for ionization; CID, collision induced dissociation; DDA, data depen-
ent acquisition; emPAI, exponentially modiﬁed protein abundance; ETD, electron
ransfer dissociation; FTMS, Fourier transform ion cyclotron resonance mass spec-
rometry; HDSS, high dimensionality small sample size problem; HUPO PSI, Human
roteome Organization Proteomics Standard Initiative; LC, liquid chromatography;
C–MS, liquid chromatography coupled to mass spectrometry; MEND, matched
ltration with experimental noise determination; MRM, multiple reaction mon-
toring; MS, mass spectrometry; MS/MS, fragment ion mass spectra of selected
recursor ions;MS-1, single stagemass spectrometry; nano-LC, liquid chromatogra-
hy using chromatographic columnof internal diameter smaller than 100m; PTM,
ost translational modiﬁcation; RSD, relative standard deviation; XML, extensible
arkup language.
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Open access under the Elsevier OA license. anism of disease, to identify compounds (biomarkers) strongly
related to the stage of the disease, its onset or progression for
diagnostic purposes, to identify novel drug targets, and to follow
the efﬁciency of treatment. The dynamic behavior of multifacto-
rial diseases requires a systems biology approach to ﬁnd reliable
biomarkers taking molecular regulatory mechanisms, compound
ﬂux and concentration changes into account [1]. To explore robust
changes in molecular systems related to disease, it is necessary to
analyzea largenumberof samples fromdifferentbiological entities,
for example from different, clinically well characterized patient
groups. Generally biomarker research is based on complex biologi-
cal samples containing a large number of diverse compounds such
as proteins, peptides and metabolites. Liquid chromatography cou-
pled to mass spectrometry (LC–MS) is one of the most widely used
comprehensive proﬁling techniques tomeasure compounds in bio-
logical materials. A single comprehensive LC–MS analysis cannot
cover all types of compounds in the samples. Instead, it measures
one class of compounds such as metabolites, lipids, and proteins
leading to biomarker discovery in this class of molecules. Even
with a technique targeting one of the above mentioned classes
of compounds, not all types of molecules can be measured due to
ionization limitations of the electrospray interface. Another chal-
lenging problem is the wide dynamic concentration range of the
compounds, which can reach 9–11 orders of magnitude in the
case of body ﬂuids such as blood [2,3]. From this wide dynamic
concentration range, modern mass spectrometers are only able to
cover 2–4 orders of magnitude. The gap between the existing and
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easurable dynamic concentration range can be reduced by using
omprehensive fractionation (4–6 orders of magnitude), multidi-
ensional chromatography (up to 8 orders of magnitude) [4] or
argeting a speciﬁc subclass of compounds, e.g. by using an afﬁn-
ty enrichment step of a certain type of glycoproteins on a lectin
olumn (up to 5–7 orders of magnitude) [5]. Another challeng-
ng factor is that although proteins and protein complexes are
irectly involved in the molecular processes of biological phenom-
na, their peptide constituents obtained after enzymatic cleavage
re measured since they are more suitable for liquid chromatog-
aphy analysis and have better ionization properties than intact
roteins or protein complexes. The most widely used endopep-
idases cut proteins at well-deﬁned sequence positions, resulting
n non-overlapping peptides mixtures, from which only a fraction
f theoretical possible peptides are detected. In this peptide cen-
ric approach also called as “bottom-up”, or “shotgun” strategy,
he quantity of initial proteins is determined indirectly based on
ew or more peptides, which leads to misleading quantiﬁcation
nd identiﬁcation in the presence of multiple highly homologous
roteins having one or few peptides in common, proteins with
ultiple splice variants, proteins presenting different degrees of
ost-translation modiﬁcations (PTMs) or in the presence of various
runcated forms of the same protein [6,7].
Biomarker discovery requires close collaboration betweenmed-
cal researchers, analytical chemists and bioinformaticians in order
o obtain the relevant molecular information related to different
spects of disease [8,9]. This includes patient cohort selection,
ampling of the biological material, sample storage, sample prepa-
ation, choice and optimization of LC–MS proﬁling platform, data
nalysis providing protein identiﬁcations, quantiﬁcation, statistical
nalysis and experimental validation of the results. Several review
apers describe the various techniques and steps of the protein
roﬁling for biomarker discovery in detail [9,10].
Bioinformatics plays an important role in this process as it has
he goal to extract quantitative and qualitative information for a
arge number of compounds (proteins and metabolites) that are
resent in complex biological samples and to select the discrimina-
ory compounds between predeﬁned sample sets. Recent advances
n sample preparation methods, liquid chromatography and mass
pectrometry instrumentation resulted in a large diversity of
cquired data. This results in a huge challenge for bioinformatics to
rovide reliable information extraction and knowledge generation
pproaches. The computational tools must evolve continuously to
eep up with the different types of generated data. Besides direct
nformation extraction and knowledge discovery from raw data,
ioinformatics plays an important role in experimental design,
uality assessment of the proﬁling platform, sampling methods,
ample handling, storage and preparation methods, or quality
ontrol of data pre-processing, statistical analysis and statistical
alidation.
This review focuses on fundamental data processing and cur-
ent challenges in supporting biomarker discovery research in
roteomics for diagnosis and treatment follow-up using LC–MS of
abel-free, shotgun proteomics data, highlighting signiﬁcant inno-
ations in the bioinformatics ﬁeld such as new algorithms, data
ntegration, high throughput automatic data preprocessing solu-
ions, quality control of different data processing modules and
ompleteworkﬂows, including assessment of the quality of sample
reparation steps andLC–MSproﬁlingplatforms [9,11–19].Wewill
lso investigate how insights from analytical chemistry contribute
o parameter optimization leading to the development of novel
ioinformatics applications that providemore accurate and reliable
nformation extraction from the raw data. Alternative approaches
ased on differential labeling of samples with reagents having the
ame chemical but different stable isotope constitution have been
overed in other reviews [20–27] and will not be treated here.3 (2011) 1209–1224
This review limits the discussion further to biomarker discovery
aiming to determine comprehensively the identity and quantity
of sample constituting proteins using analytical methods with low
sample throughput. Biomarker validation using analyticalmethods
with high sample throughput providing quantitative information
on preselected list of proteins by using analytical methods such as
multiple reaction monitoring, antibody arrays and ELISA will not
covered here. Recommendation on analytical, clinical and infor-
matics aspects of biomarker discovery and validation as well their
limitations was discussed recently by several reviews [28–34].
2. Data processing pipelines in LC–MS
LC–MS has become the major platform for analyzing sam-
ples in biomarker discovery research due to its relatively high
throughput (60–90min for analysis of one sample), sensitivity,
selectivity and coverage of many peptides and proteins [9,35,36].
In label-free LC–MS experiments, proteins or produced tryptic pep-
tides are not modiﬁed chemically and their isotope constitution is
unchanged. In label-free experiments, a large number of samples
are analyzed independently by LC–MS resulting in corresponding
raw data ﬁles. The quantitative and compound identity informa-
tion is extracted using dedicated data processing pipelines. This is
followed by matching compound quantity and identity across sev-
eral chromatograms resulting in a matrix containing quantitative
information about a large number of compounds in the different
samples. In shotgun proteomics approach the target compounds
are proteins, thereforemethods are required to determine the orig-
inal protein composition of samples and their quantities based on
incomplete set ofmeasured constituting peptides. Compounds dis-
criminating between predeﬁned classes of samples are obtained
from this matrix using dedicated statistical analysis and valida-
tion pipelines. When a systems biology approach is involved in the
biomarker discovery process, it is necessary to couple the list of
discriminating proteins to protein interaction (e.g. STRING, BIND)
or pathway (e.g. KEGG) databases [21,37] to elucidate the disease
mechanism. Fig. 1 shows the main parts of a generic proteomics
pipeline for biomarker discovery.
Most of the signals measured by LC–MS are not related to
real compounds but are part of white noise, background ions or
simply chemical noise. Different mass analyzers generate data
of different structure due to differences in scanning speed, mass
resolution, measured dynamic concentration range, changes in
peak width and resolution across the m/z domain and varying
mass accuracy [38]. The most common mass analyzers applied
in proteomics biomarker research are quadrupole, 3-dimensional
quadrupole iontrap, 2-dimensional linear iontrap, time of ﬂight,
and inductively-coupled resonance (ICR) trap family of mass spec-
trometers such as Orbitrap and Fourier transform ion cyclotron
resonance mass spectrometers (FTMS) [39]. Besides mass spec-
trometers may dispose different number of mass analyzers, and
could use different ionization method such as electrospray, ion-
spray, matrix assisted laser desorption ionization (MALDI) to name
the most frequently used method to analyze proteomics samples.
In label-free LC–MS proteomics experiments, there are two types
ofwidely usedmass spectrometry data. The ﬁrst data type contains
mass spectra obtained with one mass analyzers and is referred to
as single stage mass spectrometry data (MS-1) in the literature.
The second data type is heterogeneous and contains cyclic series
of MS-1 and precursor ion fragmented spectra (MS/MS). Each cycle
begins with MS-1 spectra, then it is followed by a deﬁned number
(generally 1–10) of MS/MS spectra obtained from the most abun-
dant ions of the MS-1 spectra. This acquisition mode is referred
to as data dependent acquisition (DDA) and abbreviated as DDA
MS/MS data. The reader is referred to dedicated books [38,40,41]
and reviews [39,42,43] for further reading on the main character-
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Fig. 1. Main modules of a generic biomarker data processing workﬂow. Raw data from the mass spectrometer are converted into one of the standard data formats such as
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s followed by labeling of the quantitative information with identiﬁcations. The stati
ist of discriminatory proteins that can be used for knowledge discovery with pathw
nteraction Database (http://pid.nci.nih.gov/).
stics of different type of mass analyzers, ionization methods and
cquisition modes. Label-free quantiﬁcation is a semi-quantitative
ethod and provides information on relative quantity changes of
he same compounds in different samples. For most applications
uch as biomarker discovery, detection of relative protein changes
s sufﬁcient information, but in system biology type of studies, the
se of stable isotope labeled standard is necessary to provide abso-
ute quantity of proteins in samples [44].
Quantitative information can be obtained from both MS-1 and
DAMS/MSdata. Quantitativemethods usingDDAMS/MSdata are
ased on spectral counting, and use the number of MS/MS spectra
hat are acquired per peptide ion(s) for the quantiﬁcation of a given
rotein. Abundant proteins generate abundant peptide fragments
hat have a higher probability to be selected as precursor ions for
DA MS/MS analysis. Nevertheless, in spite that spectral counts
hows good linearity with analyzed protein amount [45,46], the
umber of MS/MS spectra per protein suffer from saturation effect,
ndersampling, and from the limited linear concentration range
ompared to MS1 quantiﬁcation methods [47]. Spectral counting
ethods enable both absolute and relative quantiﬁcation of pro-
eins. Several bioinformatics methods use the spectral counting
pproach [46,48–50]. Exponentially modiﬁed protein abundance
ndex (emPAI) [51,52] uses the number of identiﬁed peptides to
alculate the relative molar or weight fraction of a given protein in
he respective sample. Absolute protein expression (APEX) [53,54]
ses the measured and predicted peptide counts for quantiﬁca-
ion of peptides and proteins by considering the inﬂuence of thetides are performed separately from the same ﬁle or from a different data ﬁle. This
analysis and validation is performed on the labeled quantitative data and provides a
alysis tools using for example KEGG (http://www.genome.jp/kegg/) or the Pathway
recovery of peptides from the cation-exchange and reversed-phase
LC dimensions as well as the predicted ionization efﬁciency of
the peptide in the ion source of a particular mass spectrometer.
Recently a new method, which combines the quantiﬁcation of MS-
1 and MS/MS spectra by taking the ion count in MS-1 of the three
most abundant peptides provides better quantiﬁcation for proteins
than spectral counting and gives the absolute protein quantity by
using a single protein standard [55]. DDA MS/MS measurement is
subjected to large variability regarding the identiﬁed peptide and
proteins [56], therefore more precise quantiﬁcation providing a
larger dynamic concentration range than spectral counting can be
obtained using peptide ion counts in MS-1 data. Recently, a mod-
iﬁed version of the MS/MS acquisition strategy called directed MS
was introduced with modern high resolution Q-TOF and Orbitrap
instruments. Directed MS differs from DDA MS/MS in using dif-
ferent strategy to select precursor ion for fragmentation. Instead
of using the most abundant signal intensity for the precursor-ion
selection, it performs an MS1 analysis ﬁrst and obtains an inclu-
sion list of precursor ions with retention time window after data
processing. The second MS/MS analysis is performed on precur-
sors, which are present in the inclusion list obtained previously.
This method prevents multiple reanalysis of the same peptide, and
allows identiﬁcation of low abundance components and peptides
with interesting features such as distinctive isotopic pattern, mass
defect or differently modiﬁed peptides [44,57].
Multiple reaction monitoring (MRM) is gaining popularity in
targeted quantitative analysis for small proteomes and has the
1 anta 8
a
5
t
s
m
t
P
a
t
t
c
a
l
D
o
c
p
a
i
s
a
u
S
(
S
m
m
P
d
t
[
r
c
s
p
i
a
t
i
t
b
d
b
m
c
s
m
i
t
p
a
i
d
t
p
ﬂ
b
c
o
s
S
M
m
d212 C. Christin et al. / Tal
dvantage to cover a large dynamic concentration range across
orders of magnitude [58–60]. MRM has relatively high sample
hroughput (30–60min for analysis of one sample), is able to mea-
ure few hundreds of proteins in one experiment and requires
onitoring of 5 peptides per protein selected with the help of Pep-
ideAtlas [61] or with prediction using bioinformatics tools such as
eptideSieve [62]. Monitoring of each proteolytic peptide requires
t least 3 optimized MRM transitions selected with use of a spec-
ral library [63,64]. However experimental validation of the MRM
ransitions and their selectivity for a given problem is required to
onduct reliable analysis, which can be performed by synthesis and
nalysis of synthetic peptide standards. Synthetic, stable isotope
abeled peptide standards may be used for absolute quantiﬁcation.
ue to theirwide dynamic concentration range,MRM-basedmeth-
ds can be successfully applied for validation ofmultiple biomarker
andidates [65,66]. Recent perspective paper describes and com-
ares the DDA MS/MS, directed MS and MRM based proteomics
nalysis strategies facilitating themethodological choice for exper-
mental researchers [44].
A large variety of raw data formats from different mass
pectrometer vendors were recently standardized using several
lternatives of extensible markup language (XML) formats. Widely
sed formats are mzXML [67] (developed at the Institute for
ystems Biology in Seattle Proteome Center) and mzData [68]
developed by the Human Proteome Organization Proteomics
tandard Initiative or HUPO-PSI). These two formats were lately
erged by the HUPO-PSI [69,70] into a new standard called
zML [71]. Several standardization attempts mainly by HUPO-
SI were made recently to standardize other types of proteomics
ata format such as peak list, proteomics experiments, however
hese formats are less widely used by the proteomics community
72–74].
Label-free LC–MS data pre-processing pipelines convert the
aw data into a matrix containing quantitative information on the
haracterized and preferably identiﬁed compounds in each of the
amples amenable for statistical analysis. Themainmodules of such
ipelines with the data ﬂow during this conversion are presented
n Fig. 2. This procedure begins with raw data pre-ﬁltering (such
s noise reduction, data reduction etc.), and is followed by detec-
ion and quantiﬁcation of compound-related features, and results
n feature lists characterizedamongother thingsbyquantity, reten-
ion time and m/z. These feature lists can be further reduced
y deisotoping and summing up the intensity of compound-
erived ions with different charge states. However, these steps can
e also performed after the features have been matched across
ultiple chromatograms. Peptide-related features in different
hromatograms have to be aligned or corrected in all three dimen-
ionsofMS-1data: timealignment in the retention timedimension,
ass calibration in the m/z dimension and normalization in the
ntensity dimension. The ﬁnal step is peak matching, which has
he goal to ﬁnd the same peaks in multiple chromatograms and
rovide the quantitative feature/peak matrix characterized by m/z
nd retention time values. Data processing pipeline should be ﬂex-
ble enough to adapt to the characteristics of the datasets that are
ependent on pre-analytical factors, the type of mass spectrome-
er and experimental design of the sample preparation and sample
roﬁling platform. Many data processing applications and work-
ows consisting of multiple modules, which are interconnected
y input and output parameters and data, are available free of
harge or commercially. Work has been dedicated to construct
ptimized data analysis pipelines for label-free LC–MS [27,48],
uch as Viper [75], OpenMS [76–79], mzMine [80,81], XPRESS [82],
IEVE, Superhirn [83], Census [84], MapQuant [85], SpecArray [86],
sMetrix [87], PEPPeR [88] or XCMS [89] originally developed for
etabolomics but also applicable to the analysis of proteomics
ata.3 (2011) 1209–1224
2.1. Data reduction
MS-1 data is three dimensional in nature with retention
time, m/z and ion count dimensions. This information is gen-
erally stored with succeeding mass spectra storing information
in mass–intensity pairs. This raw data is often converted into a
two-dimensional regular matrix, with a procedure called meshing,
resulting in an intensity matrix, where the columns and rows cor-
respond to a given mass and retention time. Two types of raw mass
spectrometry ﬁles are provided by the mass spectrometers. Proﬁle
data contains all acquired data points, and centroid data is pre-
processed by the acquisition software generally with algorithms
operating on single MS spectra. Storing data in centroid mode may
result in loss of information for certain data processing algorithms,
whichperformpeakdetection inbothdimensions, but reduces con-
siderably the size of the acquired data. Data processing algorithms,
especially those that arewritten in interpreted, complex high-level
programming language such as R or Matlab, generally load all data
into the computer memory and are thus limited by the available
memory. These algorithms apply data reduction to ﬁt the amount
of data to the available memory. This is most frequently done by
binning [18,80,89]whichsums intensitiesbetweenpredeﬁnedcon-
secutive and disjoint mass domains. This works well when most of
thedata points of theGaussianpeaks arewithin themass borders of
the bin, but leads to ﬂuctuating saw tooth type splitting of the peak
for centroiddatawhen thebinborders fall in theﬂuctuationdomain
of the peak maxima along the consecutive m/z traces. This prob-
lem can be avoided by using a two-dimensional Gaussian ﬁlter that
smoothes ﬂuctuations in both retention time and mass dimensions
thus avoiding the sawtooth splitting of peaks (for details see Fig. 3).
Other approaches to reduce the intensity ﬂuctuation of binning
were reported recently, however each of them is computationally
intensive and results in varying bin widths [90–92]. The quality of
the LC–MS data determines the accuracy of feature detection and
quantiﬁcation. Choosing between binning or 2-dimensional Gaus-
sian smoothing of the data has a dramatic effect on quantiﬁcation
when data reduction is applied. Data processing pipelines using
programming languages with the possibility to allow user-deﬁned
memorymanagementareadvisedas is theuseof streaming toover-
comememory limitations in the case of proﬁle data at their original
resolution. Streaming is a programming techniquewhich reads and
processes only part of the data in one time, and after processing,
the results of each part are written on a continuously growing ﬁle.
The algorithm goes over all data parts resulting in the complete
processing of the ﬁle, Streaming allows to process large ﬁles inde-
pendently of the available amount of RAM. Data reduction should
be avoided if possible due to information loss.
2.2. Noise characterization, feature detection and extraction
A chemical compound with a given charge and isotope distribu-
tion is represented as a three-dimensional Gaussian peak in MS-1
and is often denominated as ‘feature’ in the data processing world.
Due to the natural isotope distribution and to the occurrence of
multiple charge states, one chemical compound results in multi-
ple Gaussian peaks with the same retention time. These features
must, at the ﬁrst level, be discriminated from noise to determine
their main characteristics such as quantity represented by the peak
volume, area or height, retention time and mass to charge ratio
of the center of the peaks, as well as the extension of the Gaus-
sian peaks in the m/z and retention time dimensions. The second
level is the extractionof compoundcharacteristics related to charge
state determination and the identiﬁcation of isotope peak clusters.
First level feature characteristics are obtainedby all data processing
pipelineswhile extractionof second level characteristics is optional
and can be performed at a later stage after matching the same
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Fig. 2. Main modules of quantitative data processing pipelines. Raw data in standard format (mzXML, mzdata.xml or mzML) may be recalibrated for increased mass accuracy
and converted into a resampled matrix, where intensity values are in the matrix, rows (or columns) correspond to m/z and columns (or rows) to retention time values (exact
values are stored in separate vectors). This matrix may be optionally subjected to data reduction and noise ﬁltering. The obtained data matrix is subjected to peak picking
(ellipse in green) and peak quantiﬁcation providing a peak list containing the most important characteristics of the identiﬁed peaks, usually retention time and m/z values
of the peak centroid, peak quantity expressed in peak height, area or volume, and optionally peak extension in the m/z and retention time dimensions, as well as charge
state and an index that is used to couple peaks of the same isotope cluster or different charge states of the isotope clusters to the same compound. Alignment in the three
available dimensions (time alignment, mass calibration and intensity normalization) can be performed either at the peak list or at the raw data ﬁle level (ellipses in orange).
The aligned and normalized peak lists of different samples are then matched (ellipse in purple), resulting in a quantitative peak matrix containing information about the
matched peaks in different samples, where columns (or rows) correspond to different samples and rows (or columns) to different peaks, which are later coupled to identities
at the peptide and protein level. This quantitative peak matrix is used for statistical analysis to identify discriminating peaks between predeﬁned classes of samples. The
ﬁgure indicates the two most common data ﬂows with the order of modules using blue and red arrows. Dashed arrows indicate optional linkage of modules. Another order
of the modules and data ﬂows is possible as well the integration of different modules, such as time alignment with peak matching. (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of the article.)
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Fig. 3. Raw centroid ion trap MS-1 LC–MS image of depleted, trypsin-digested human serum obtained after binning (summing up intensity across 1 amu intervals having
borders at fractional decimal of 0.5 m/z for each integer m/z value), (a) and after applying a two-dimensional Gaussian ﬁlter using the same degree of data reduction in the
m/z dimension as for binning (b). Binning results in noisy data, which leads to a poor feature detection and quantiﬁcation efﬁciency, in contrast to the data obtained after
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he bins. This ﬂuctuation results in a saw tooth peak shape in adjacent extracted ion
lgorithms recognizing Gaussian peak shapes in individual mass traces.
eature of the same compounds in multiple chromatograms. If low
esolution mass spectrometry data or considerable data reduction
n the mass dimension is used for high-resolution mass spectrome-
ry data, isotope peaks may collapse into a single Gaussian peak or
nto series of strongly overlapping Gaussian peaks. In this type of
ata, peak detection algorithms will detect the isotope peaks clus-
er as one Gaussian peak and provide the average mass of the peak
luster.Noise characterization is important and can be regarded as
part of the peak detection step, which tries to discriminate
oise from compound-related features signal. Noise in LC–MS data
riginates from different sources [93–95]. To discriminate noise
rom features, it is useful to take the noise model of the differ-eak maxima in between mass spectra in two adjacent bins, (c) as represented in a
he highest intensity of the peak in centroid data ﬂuctuates between the border of
matograms, which will lead to poor performance in case of use of feature detection
ent mass analyzers into account in the peak detection algorithm
[96]. Mass analyzers and detectors deﬁne the background white
noise. Another type of noise of chemical origin is called chemi-
cal noise. Chemical noise originates from molecule clusters formed
during electrospray ionization (e.g. solvent clusters), from chem-
ical contaminations inside the mass spectrometer (e.g. in the ion
source), from the chromatographic column or from the ambient
air such as polydimethylcyclosiloxanes, phthalate or the plasti-
cizers di-n-butyl-phthalate and (di-(2-ethylhexyl)-adipate) [9,97].
Ion suppression effect [98] distorts the compound-related signals
and is dependent on sample composition and therefore also on the
upstream sample preparation steps. Formation of eluent ion clus-
ters during electrospray ionization and elution of contaminants
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rom the chromatographic columns are highly inﬂuenced by the
ater/acetonitrile ratio of the eluent, which changes gradually
uring reverse-phase LC–MS. This results in varying chemical back-
round noise in both the retention time and m/z dimensions.
ontaminants in the LC eluent or in the ambient air result in stripes
f constant m/z across a large part of the retention time axis.
Numerous denoising and baseline (average noise level) sub-
raction algorithms exist in the literature, such as moving average
18,99], Savitzky–Golay ﬁlters [100] or entropy-based noise reduc-
ion [101] to name a few examples. As these algorithms will not be
overed in this review, the reader is referred to reviews and publi-
ations on this topic [102–107]. It is important to choose baseline
emoval and denoising algorithms, which do not alter the quanti-
ative information of the peaks. Many feature detection algorithms
ere developed to discriminate compound-related peaks from
oise since the introduction of LC–MS. These algorithms match the
sotope pattern of compounds in the m/z dimension (1D peak pick-
ng) or the peak shape based on extracted ion chromatograms (2D
eak picking) or on the full 3-dimensional LC–MS data (3D peak
icking) to detect Gaussian-shaped peaks. Algorithms that match
sotope patterns have the disadvantage that they do not use the full
-dimensional structure of MS-1 data, but apply peak detection on
ndividual MS spectra, which are subject to a high noise content.
IPER [75], SpecArray [86] and SuperHirn [83] are examples of data
rocessing workﬂows using peak picking algorithms based on iso-
ope pattern matching. Examples of 2D peak matching algorithms
ased on extracted ion chromatograms are the M–N rule [18],
nd the matched ﬁltration with experimental noise determination
MEND) algorithms [104]. M–N rules detect an LC–MS feature in
xtracted ion chromatograms when the intensity exceeds the local
aseline N times for M consecutive points. MEND matches Gaus-
ian peakproﬁles onnoise deﬁltered extracted ion chromatograms.
nother example for a 2D peak shape matching algorithm is based
nwavelet decompositiondevelopedbyCoppadonaet al. [105,106]
o remove noise and deﬁne the baseline of extracted ion chro-
atograms. Finally the algorithm uses the difference of baseline
nd denoised data to detect peaks. Other peak detection meth-
ds use modiﬁed version of the binning algorithms adapting the
in size to the peak width in mass dimension. This type of algo-
ithmdetects peaks either by locating regions in centroid datawith
arge amount of missing noise in mass dimensions and having high
ntensity signalwith closemass value in consecutive retention time
oints [92], or by peak detection using Kalman ﬁlter to extract Pure
on Chromatograms containing only information on peaks without
oise [91] and by centWave method detecting peaks containing
egions based on analysis of mass variation of centroid intensities
n the retention time dimensions and identifying the peaks using
ontinuous wavelet transformation and optionally Gauss-ﬁtting in
he chromatographic domain [90]. Three-dimensional peak detec-
ion methods using shape matching are applied in MapQuant [85],
hich ﬁts a 3-dimensional Gaussian curve on local maxima. The
pLCMSpipeline [103] uses a two-dimensional density kernel func-
ion to identify groups of peaks, while MZmine [80,81], msInspect
108] and LCMS-2D [107] use peak shape in the retention time
imension and the isotopic pattern in the m/z dimension. OpenMS
76–79] uses a three-dimensionalwavelet function taking the aver-
geof thepeptide isotopecomposition intoaccountbyconstructing
mixture Gaussian model. There are many other peak detection
ethods and the reader is directed to a recent review on the topic
109].
To compare the performance of different peak quantiﬁcationlgorithms, the peak picking methods of msInspect and mzMine
ere compared by analyzing a tryptic digest of a mixture of 48
ecombinant proteins resulting in ∼800 peptides by FTMS in MS-1
nd MS/MS mode with the help of a receiver operating characteris-
ics (ROC) curve. The comparison showed that the isotope pattern3 (2011) 1209–1224 1215
matching algorithm of msInspect was superior in performance to
mzMine using predeﬁned peak shape template for peak detection
[109]. Peak tailing or fronting and saturation of the detector lead to
peak splitting for some features. The occurrence of peak splitting
depends on the peak detectionmethod and should be evaluated for
each algorithm using different types of data. The algorithm devel-
oped by de Groot et al. [110] uses K-mean clustering to correct for
split peaks and to correct peaks that were incorrectly aligned in
the retention time dimension. Other quality control criteria appli-
cable only to high resolution data such as Orbitrap and FTMS use
mass deviance to assess if a detected compound correspond to real
peptides [111]. Mass deviance is the difference of the decimal frac-
tion of the monoisotopic peak of the detected compound and the
nearest theoretical tryptic peptide. Overlaying on a part of a 2 or
3 dimensional MS-1 raw or pre-processed data with the location
and extent of detected features as it possible in OpenMS frame-
work enable to assess visually the accuracy of peak picking method
[76,78,79].
2.3. Alignment of LC–MS images
Three-dimensional MS-1 LC–MS images are prone to nonlinear
shifts in all of the three dimensions. In the mass dimension align-
ment is based on proper calibration of themass analyzer preferably
with internal standards. In the intensity dimension, normalization
maybeused, and in the retention timedimension, timealignment is
necessary. Mass calibration should provide alignment to the exact
mass. Intensity normalization could be relative to compare rela-
tive intensity of the peptides and proteins, but may provide exact
alignment if absolute quantiﬁcation is required. Retention time
alignment is relative, in spite of the fact that retention time indices
may be used for identiﬁcation [112]. After successful alignment
of all LC–MS chromatograms common peaks in different chro-
matograms are matched and their relative or absolute quantities
are reported in the form of a matrix that is amenable to statistical
analysis. In this matrix rows (or columns) correspond to samples
and columns (or rows) to features or peptide peak identities. Align-
ment of LC–MS images can be performed with different goals in
mind depending on the experimental design, such as to transfer
peak identity information from separate MS/MS datasets to MS-1,
or to combine data from several chromatograms corresponding to
the fractions of a 2D-LC–MS analysis of a single sample.
2.3.1. Mass calibration
The m/z dimension is the most stable dimension toward shifts.
The absence of shifts does, however, not mean that the measured
values are accurate. This requires calibration of themass spectrom-
eter, preferably with internals standards that are present in each
spectrum. Mass analyzers are, however, measuring instruments
that are prone to small nonlinear shifts requiring automated algo-
rithms to compensate for inaccuratemass calibration or to enhance
mass accuracy, especially for high resolution mass spectrometers.
Ions of chemical backgroundnoise originating fromeluents or from
the ambient air such as polysiloxanes or continuously added cali-
bration standards can be used for mass calibration and to increase
mass accuracy. A polynomial mass calibration function was used
by Scheltema et al. [113] to increase mass accuracy of metabo-
lites measured with an Orbitrap mass spectrometer. The algorithm
improved mass accuracy from 1–2ppm to 0.21ppm using back-
ground ions, such as polysiloxanes, as internal standards. Haas
et al. [114] usedpolydimethylcyclosiloxanes to enhancemass accu-
racy of MS/MS spectra and reported a higher identiﬁcation rate of
peptides. Another strategy involves the use of already identiﬁed
peptides as calibration standards, a strategy that was successfully
applied to improve peptide identiﬁcation based on MS/MS spectra
[115]. An interesting approach developed by Dijkstra and Jansen
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116] superimposes isotopeclustersof the samepeptideatdifferent
harge states in SELDI–TOF–MS spectra to improve mass accuracy.
his approach can be easily adapted to spectra obtained with other
nstruments and electrospray ionization as multiple charging of
eptides is a common phenomenon.
.3.2. Intensity normalization
High throughput LC–MS data comes with nonlinear and sys-
ematic bias in recorded peptide ion intensity, affected mostly
y differences in injected sample amount, differences or drifts in
onization efﬁciency, differences in ion transmission efﬁciency or
etector saturation, and carryover between LC runs. The resulting
ias should be corrected in order to enhance statistical classiﬁca-
ion accuracy. Systematic bias due to adifference in injected sample
mount should be minimized, e.g. by determining the injected
mount with a total protein assay or by taking the area under
he curve of the UV trace of a previous analysis into account.
ometimes normalization can be based on a single factor such as
he average or median abundance of peptides derived from so-
alled ‘housekeeping proteins’ or other compounds that are known
ot to be affected by the investigated disease or sample dilution
actor, such as creatinin in urine samples [117]. However, all inten-
ity normalization approaches have drawbacks, e.g. normalization
ased on housekeeping proteins should not be applied for samples
hanging in constitution of these proteins considerably. Remain-
ng nonlinear bias can be removed using normalization methods
pplied in microarray analysis [118] e.g. by performing a nonlin-
ar regression of matched peak intensities in two samples with the
ame or close composition. Various normalization methods were
eveloped and assessed for label-free quantiﬁcation using LC–MS
100,102,119–121]. Linear regression can be applied to bias that
as a linear pattern across analyses such as sample carryover in the
rapping column. Nonlinear bias caused e.g. by detector saturation
an be resolved by non-linear or local regression techniques, and
uantile normalization may be used to transform peptide quantity
istribution of all sample to the same distribution using quantile
lots. Callister et al. [120] compared different normalization meth-
dsusingLC–FTICR–MSdatasets andconcluded that global or linear
egression worked best in most cases when applied iteratively. A
ecent study by Kultima et al. [119] compared 10 different nor-
alization methods using datasets from mouse, rat and quail that
ere analyzed by a nano-LC–MS system coupled either to a Q-TOF
r to an LTQ mass spectrometer. Karpievitch et al. [121] developed
normalization method based on singular value decomposition
o remove systematic and nonlinear bias to avoid overﬁtting by
imension reduction for label-free LC–MS proteomics samples.
n general, normalization algorithms use matched peak matrices.
herefore normalization procedures are implemented after peak
atching and prior to the statistical analysis.
.4. Time alignment
The retention time of compounds is subjected to considerable
on-linear shifts between LC–MS experiments and requires partic-
lar attention and more sophisticated alignment algorithms than
he two other domains. Complex proteomics samples, such as
erum and urine, contain several tens of thousands of peptides,
o that even small retention time shifts may result in serious peak
ismatching, if peak matching is only based on the retention time
nd m/z coordinates across multiple samples. Retention time shifts
re due to parameters of liquid chromatography that are hard to
ontrol, such as small changes in eluent composition, pH, column
geingor temperature changes andhave ahighlynon-linear behav-
or, especially when the combination of a trapping and analytical
olumn system is used. Accurate algorithms to correct retention
ime shifts is one of the most critical points of data processing to3 (2011) 1209–1224
provide accurately matched peaks and quantitative data that are
suitable for statistical analysis.
The goal of time alignment is to ﬁnd the maximum overlap
between similar peaks in different chromatograms and provide a
retention time transformation function,which canbeused either to
change the retention times of all peaks in a peak list, or to change
the associated retention time of mass scans in the raw data. The
major difference between time alignments methods using MS-1
data is how many data dimensions they use in their beneﬁt func-
tion to drive the time alignment procedure. Earlier developments
considered only 1-dimensional data next to the retention time
dimension in their beneﬁt function (e.g. the TIC or BPC) [122–130].
Recent algorithms use two-dimensional proﬁles that take the sepa-
ration of compounds in the mass and the retention time dimension
into account. The latter approaches provide more accurate time
alignment of highly complex LC–MS ‘omics’ data. Two-dimensional
alignment algorithms differ in terms of whether they use the raw
data, pre-processed data obtained after noise ﬁltering and data
reduction [94,95,100,126,127,131–133] or peak lists after the peak
detection step [77,134,135].
A large number of algorithms were developed to deﬁne the
optimal search space for non-linear retention time correction,
such as Correlation Optimized Warping [95,122,126,128,129,135],
Parametric Time Warping [94,124], Dynamic Time Warping
[94,100,125,127,129–133,136], a geometric approach based on
pose clustering [77,137], Loess regression on matched compound
pairs [134], the Continuous Proﬁle Model combined with a Hid-
den Markov Model [138] to list a few. Time alignment based on
DDA MS/MS data uses the correlation between MS/MS information
of the same compound [88,139]. Other types of algorithms create
retention time and mass tags by normalization of retention time
and accurate mass. These tags are subsequently used to align mul-
tiple LC–MSdatasets in both them/z and retention timedimensions
or through comparison with a database [136].
Generally time alignment is performed by selecting one chro-
matogram as reference and aligning all others to that reference
pair wise. This approach requires the a priori selection of a ref-
erence chromatogram and must assess how selecting different
reference chromatograms affects the quality of time alignment.
Robust time alignmentmethods shouldnot dependon the choice of
the reference chromatogram [94,95]. The Continuous ProﬁleModel
developed by Listgarten et al. [138] does not use a reference chro-
matogram, but performs the alignment of all chromatograms in
one step. The performance of different time alignment algorithms
depends on many parameters, such as the number of common
peaks shared between chromatograms, the complexity of the sam-
ples, the compound distribution in retention time–m/z space, the
compound concentration variability and noise distribution. A com-
parison of different algorithmswith different characteristics shows
that time alignment methods that take the three-dimensional
nature of MS-1 data into account perform better for complex pro-
teomics samples with large compound concentration variability
[94,95,135].
In most studies the same chromatographic columns and strict
standard operating procedures are applied in order to lower ana-
lytical variability. It is rare that the elution order of compounds
changes under these conditions and a monotonic time alignment
function is appropriate [140]. However the elution order may
change during extensive studies over a long period of time or when
different types of columns are used (e.g. when using different types
ofn-octadecyl bonded silica reverse phase stationaryphases) [141].
It is also known that thepHof the eluenthas adramatic inﬂuenceon
the selectivity ofRP columns [142,143], and this can lead toa chang-
ing elution order when analysing complex proteomics samples.
Inversion of the elution order of peptides ormetabolites is not com-
monly reported and thus probably not recognized. It is important in
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he future to explore this phenomenon in greater detail, especially
hen different types of LC RP-C18 columns are used within one
tudy or when large-scale studies are performed in different labo-
atories. If peak elution order changes are frequently observed, this
ould require novel time alignment algorithms, which can deal
ith peak elution order changes adequately. For further reading
n time alignment the reader is referred to specialized reviews
140,144] and articles presenting results from performance com-
arisons of different time alignment methods [94,129,137].
The quality of time alignment is generally evaluated by visual-
zation of the entire chromatogram, or by visualization of common
eaks to assess the local time alignment accuracy. Co-injected
tandardpeptidesorpeptidesderived fromhighlyabundanthouse-
eeping proteins can also be used for this purpose. Comparing the
uality of different time alignment algorithms in such a way is a
aunting task and visualization of entire chromatograms does not
lways allow a proper quality control of the time alignment results.
quality assessment method based on the sum of the overlapping
eak area between pairs of chromatograms provides a global read-
ut of alignment quality and permits comparison of the relative
erformance of various types of algorithms [94,95]. Similarity score
alculated after time alignment for assessing the quality of time
lignment, may also be used to assess eventual bias in experimen-
al design and to detect whether there is a systematic difference
etween sample replicates or injection order [145].
.5. Peak matching
The peak matching process identiﬁes common peaks in differ-
nt chromatograms based on proximity of aligned retention time
ndmass or peptide identity based onMS/MS datawhen this infor-
ation is linked to the peak list. Numerous clustering algorithms
ave been applied to match peaks such as K-mean, hierarchical
r pose clustering [102,144,146]. The procedure provides a list of
lusters of the same compounds in different chromatograms, from
hich a quantitative featurematrix is constructed. Thematrix con-
ains a quantitative measure of the feature and rows (or columns)
hat correspond to the samples and columns (or rows) to the fea-
ures (e.g. peptide ions) characterized by retention time and m/z
alue. Features in this matrix can be further processed by deiso-
oping and by integration of different charge states of the same
ompound resulting in a quantitative peptide matrix, which fur-
her may be combined with identiﬁcation results. Deisotoping and
echarging can also be performed at peak list level prior to the peak
atching procedure. MS-1 data processing pipelines must assign a
uantitative value to peaks that do not have a correspondence in
ll chromatograms. Somepipelines extract noise at the correspond-
ng location, while others ﬁlter out peaks found only in minority of
amples to avoid bias for single and rare events in the subsequent
tatistical analysis.
.6. Peptide and protein identiﬁcation
Peptide and protein identiﬁcations are generally performed
sing information from MS/MS spectra. Before identiﬁcation,
S/MS spectra are ﬁltered to remove noise and the cleaned spec-
ra are used for the identiﬁcation process. The most widely used
rotein identiﬁcation approach is database search, where lists of
eaks in MS/MS spectra are compared with molecule fragments
btained by in-silico fragmentation of sequences stored in the
atabase [147–149]. This comparison may be performed by cal-
ulating a similarity score between the in-silico fragments and the
easured fragments, and the peptide with the best match receives
he highest score. A threshold is used to limit the number of false
ositive identiﬁcations while at the same avoiding to penalize true
ositives. It is thus noteworthy that so-called identiﬁed peptides3 (2011) 1209–1224 1217
and proteins always contain a chance that they are false positives.
This matching approach is used by the Sequest algorithm [150].
Interpretative models use the assumption that MS/MS spectra con-
sist of a continuous series of fragment ions that can be interpreted
as a partial short amino acid sequence tag of the intact peptide.
PeptideSearch [151], MS-Seq [152] and GutenTag [153] use this
strategy. Stochastic model-based algorithms use probability esti-
mates for peptide fragmentation and subsequent predictions of
the resulting mass spectra that are compared with the measured
MS/MS spectra. SCOPE [154] andOlav [155] (the basis of the Phenyx
search engine) are examples of this category. Finally programs
such as Mascot [156] and the open source OMSSA [157] apply sta-
tistical and probabilistic models using empirically generated ion
probabilities of peptide sequences stored in the database. Spec-
tral library search algorithms represent another category of peptide
identiﬁcation algorithms. These algorithms compare noise-ﬁltered
MS/MSspectrawithdatabases containinghigh-quality, experimen-
tal MS/MS spectra using similarity scores [158,159]. Clustering
MS/MS spectra of the same peptide can enhance the probability for
successful peptide and protein identiﬁcations signiﬁcantly while
at the same time decreasing the number of spectra that are sent
for database search by one order of magnitude [160]. Database
search and spectral library search algorithms have limited capa-
bility to identify peptides with PTM, since the peptide with a given
PTM should be either present in the database or deﬁned by the
user prior to the search. Open modiﬁcation search programs such
as Popitam [161] and Inspect [162] use MS/MS spectra of already
identiﬁed peptides and allow unexpected mass shifts in the frag-
mentation pattern of the peptides due to PTM. Open modiﬁcation
search algorithms are, however, computationally more intensive
than database search algorithms and therefore they generally use
a limited number of peptide sequences for identiﬁcation. De novo
sequencing algorithms such as PEAKS [163,164], PepNovo [165],
EigenMS[166], Luteﬁsk [167], Sherenga [168],MSNovo [169], PILOT
[170], NovoHMM [171], and AUDENS [172] use only information
from the experimentally acquired MS/MS spectra and basic con-
stants such as the mass of the amino acids to elucidate the most
probable sequence of the fragmented peptide.
A simple peptide identiﬁcation method using label-free MS-1
data exploits so-called accurate mass and time tag (AMT) infor-
mation that is calculated from accurate mass and retention times
with or without normalization to match pre-identiﬁed peptide
sequences in a database to the newly acquired data [112,173,174].
This identiﬁcation strategy has the advantage to perform MS/MS
based peptide and protein identiﬁcations on pooled or represen-
tative samples using time-consuming proﬁling techniques with a
large peak capacity (e.g. 2D-LC–MS with DDA MS/MS data acqui-
sition) followed by the quantitative analysis of a large number
of samples with faster LC–MS platforms operating in MS-1 mode,
which cover a larger measured concentration range. Basically this
technique can be considered as a generic peptide and protein
identiﬁcation transfer system that uses mass and retention time
information for the matching, and has the disadvantage that the
identiﬁcation transfer may be sensitive to the LC parameters and
that high-resolution mass spectrometers with high mass accuracy
(FTMS or Orbitrap) are required to reduce the chance for incorrect
matching at an acceptable rate [173,174]. In most case normal-
ization of the retention time is performed through regression of
the observed and predicted retention times using training datasets
and a neural network for retention time prediction. The databases
containing peptide identiﬁcations with AMT tags are generally
obtained from different analyses by generating reference maps
[112,175].
To decrease false positive identiﬁcations, Scaffold [176] com-
bines identiﬁcation results of different database search programs
such as Sequest [150], Mascot [156] or X! Tandem [177] (version
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erforming parallelized processing is called X!! Tandem [178]) and
alculates a composite probability score, providing more reliable
rotein identiﬁcation compared to the single score of one pro-
ram. A protein identiﬁcation score is constructed from identiﬁed
eptide scores and relates to the probability that a given identi-
cation is a true positive. With its combined scores, Scaffold also
rovides amore reliable grouping of peptides for protein identiﬁca-
ion. The probability for false positives can be further decreased by
omparing themeasured andpredicted retention times of the iden-
iﬁed peptides. Retention time prediction algorithms use statistical
ethods based on quantitative structure–retention time relation-
hips [179], which are in turn based on a large number ofmolecular
escriptors or training datasets and regression methods taking the
mino acid composition of the peptide into account [180,181].
Database search algorithms are biased to the protein present
n the database and are poor to detect splice variants and pro-
eins with PTMs. In order to be able to identify proteins with splice
ariants and PTM, the Swisspit [182,183] workﬂow combines the
esults of identiﬁcations obtained with the Phenyx [155] and X!
andem [177] database search type algorithms with the Popitam
nd Inspect open modiﬁcation search type algorithms. This is a
ombination of ﬁrst assigning identiﬁcations using database search
rograms and subsequently submitting unassigned MS/MS spectra
o openmodiﬁcation search algorithmswith restriction to use pep-
ide sequences identiﬁed previously by both database search tools.
he Swisspit [182,183] workﬂow resulted in a higher identiﬁcation
ate of 77% for small well annotated PTM-rich lens datasets com-
ared to 21% obtained with the combination of the two database
earch programs only.
Another ingenious approach use spectral network analysis for
eptide identiﬁcation [184]. This method ﬁnds pairs of MS/MS
pectra that differ only in onemodiﬁcation or amino acid by search-
ng for corresponding b- and y-type fragment ions. From multiple
aired spectra, a network is constructed and is used to propagate
eptide identiﬁcation from peptide without PTM to the same pep-
idewithdifferentnumbersofPTMoraminoacids changes. Spectral
etwork analysis was further adopted to include data from mul-
istage MS/MS such as MS3 or MS4 in the interpretation [185].
pectral dictionaries extend the sequence tag approach by gen-
rating sets of full-length peptide de novo reconstructions. These
pectral dictionaries are then searched in a database equippedwith
ash table or sufﬁx tree providing a fast identiﬁcation algorithm,
ith high true positive identiﬁcation rates [186].
Since database search algorithms always provide a list of iden-
iﬁed peptide and proteins with given scores, it is important to test
he statistical signiﬁcance of the obtained score against a decoy
atabase containing incorrect protein sequences obtained, for
xample, by reversing or randomizing existing protein sequences
187–190]. The presence of highly homologous proteins repre-
ent an actual challenge for the protein identiﬁcation software,
herefore in case of list of proteins with high sequence homology
he results should be taken with precaution specially, when only
eptides shared with other proteins are identiﬁed. The reader is
eferred to dedicated book and reviews for further reading on the
eptide and protein identiﬁcation algorithms [147,148,191–193],
uality controlmethods [194] and inﬂuenceofparameters affecting
he quality of MS/MS [195].
. Statistical analysis and validation
.1. Coupling feature quantiﬁcation with peptide and protein
dentity
Quantitative feature matrices should be ﬁrst transformed to
uantitative compound matrices by summing up the quantity of
sotope clusters and different charge states of the same compound3 (2011) 1209–1224
(one signal per compound matrix). Peptide quantity should be fur-
thermatchedwithcompound identityat thepeptideandultimately
the protein level. Regarding protein quantity, different methods
can be used starting from summing up the intensity of constituting
peptides to taking the sum of the three most abundant peptides
of each protein [55]. Mapping peptide identity to the quantity of
extracted features involves several steps. Precursor ion mass of a
given charge state should be matched to the isotope cluster of the
same charge and the corresponding quantity (e.g. represented by
the sum of all isotopomer peak height or the peak height of the
monoisotopic peak only) of the isotope cluster should be combined
with the quantity of the other isotope clusters of the same peptide
with different charge state. This step is followed by the determina-
tion of all identiﬁed peptides constituting individual proteins. The
peptide centric nature of the shotgun proteomics approach makes
quantiﬁcation of original protein mixture challenging in the pres-
ence of multiple proteins with high sequence homology, truncated
protein forms, proteins having different PTMs or multiple splice
variants [6,7]. For accurate protein quantiﬁcation, with either MS1
or spectral counting methods, precise peptide and protein iden-
tiﬁcation including detection of all protein variants is necessary,
because the identiﬁed peptides will provide the list of peptides
unique for theprotein andpeptides that are sharedbetween several
proteins, andwhichwill allow accurate quantiﬁcation of all protein
variants. Recently Zhang et al. [196] evaluated different strategies
for spectral counting quantiﬁcation and found that the most accu-
rate quantiﬁcation was obtained by adding to the spectral counts
of peptides unique for the protein, the corresponding molar pro-
portion of the spectral counts of peptides shared between different
proteins. The identiﬁcation of exact protein form is also important
for the development of accurate targeted MRM assays, while the
presence of peptides shared between proteins could bias consider-
ably the measured protein quantities [6,7,60]. A recent review by
Podwojski et al. [197] deals with this problem in detail.
Annotated quantitative peptide matrices can be obtained by
other methods [198], than those based on MS-1 data, such as
the already mentioned MRM-based methods, spectral counting
algorithms and by quantifying spot intensity in 2-dimensional gel
electrophoresis coupled with peptide ﬁngerprinting or LC–MS/MS
identiﬁcation [199–201]. Immunochemical techniques based on
antibody arrays are especially interesting for the targeted proﬁling
andvalidationofproteins in complexbiological samples [202–204].
Quantiﬁcation methods provide absolute or relative protein quan-
tities or other type of biodescriptors if the goal of the analysis is to
compare biological pattern for sample classiﬁcation [205].
3.2. Sample/feature dimensions and feature
selection/transformation methods
The main application of statistical analysis, also called post-
processing methods, is to ﬁnd peptides and proteins that
discriminate between different groups of preclassiﬁed samples.
Discriminating peptides or proteins are selected from the common
peaks after data processing, which means that the validity of the
ultimate statistical result depends on thequality of data processing.
Statistical analysis of quantitative proteomics experiments suffer
from the high dimensionality given by the large number of identi-
ﬁed peptides and proteins accompanied by a much lower sample
size. Due to this characteristic, processed proteomics data are often
referred as megavariate data [206,207] leading to a high dimen-
sionality small sample size (HDSS) problem [146]. HDSS is themain
reason, whymost of thewidely used classiﬁcationmethods such as
linear discriminant analysis cannot be directly applied to analyze
quantitative proteomics datasets. In datasetswithHDSSproperties,
a large number of compounds may be found to differ signiﬁcantly
between predeﬁned classes of samples using, e.g. the univariate
anta 83 (2011) 1209–1224 1219
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Fig. 4. Main steps of the statistical analysis and validation strategy for proteomics
data suffering from the HDSS problem. Panel (a) gives a schematic overview of the
modules for supervised statistical analysis and validation. The core (modules 1–3)
represents the statistical analysismodules for feature selection (module1; optional),
classiﬁcation (module 2) and biomarker selection (module 3; optional). The outer
part represents modules for statistical validation comprised of a model selection
module (4), amodule to assess performance of the classiﬁer (5) and amodule assess-C. Christin et al. / Tal
-test, but they may not be conﬁrmed in other independent set
f samples. Disease-related changes generally affect a small por-
ion of proteins and peptides in living organisms, which represent
he truly discriminating molecules between predeﬁned groups of
amples, and which stay true when measuring new sample sets.
o ﬁnd a small number of truly discriminating proteins among a
ery large number of other non-disease related proteins in datasets
ith HDSS, it is necessary to either use statistical methods that are
nsensitive to uninformative features (noise) or to reduce the num-
er of features (dimensions) prior to the actual statistical analysis
o a number that does not exceed the number of samples (indepen-
ent observations). Only very few methods such as Support Vector
achines [208–210] or Learning Vector Quantizations [211,212],
laim tobe insensitive to a large amount of noise peaks contained in
DSS datasets and generally do not require upfront feature selec-
ion. Other methods require dimension reduction, which can be
erformed by removing uninformative peaks and selecting statis-
ically relevant discriminative peaks (so-called feature selection)
r to perform data transformation to accentuate class differences.
eature selection methods are most widely used [102,213–216],
ince these methods not only help to remedy the HDSS problem,
ut also provide a list of discriminatory peaks. Selected features
orresponding to a limited number of biomarker candidates must
e validated by measuring a larger sample set with fast and tar-
eted analytical methods such as LC–MS/MS in MRM mode [3]. The
esults can also be used as input for databases and algorithms to
ink them to biochemical, secretion, molecular interaction or sig-
aling pathways that may be involved in disease-related biological
rocesses.
Feature selection can be performed in a supervised manner
sing univariate or multivariate selection algorithms. Univariate
ethods assume that features are mutually independent, so that
ach feature is evaluated individually based on its individual rele-
ance to discriminate between predeﬁned classes of samples. The
implest method for feature selection is the univariate Student’s
-test, which must be corrected for multiple testing. In context
eature selection methods (multivariate methods) take the inter-
ependency between features into account, when evaluating the
ndividual strength or rank of a given feature. Collective assess-
ent and selection of variable subsets is another type of feature
election. This method selects a feature subset by evaluating all
ossible correlations or other forms of dependencies between fea-
ures. Since the number of subsets increases exponentially with
he number of features, it becomes an exhaustive task to evaluate
ll possible subset combinations in the feature space. Therefore,
ost collective feature selection methods are based on heuristic
earch strategies, such as forward selection and backward elimina-
ion [217]. Forward selection methods start with an empty feature
ubset and add features step-by-step to maximize a predeﬁned
coring function. The procedure is stopped when newly selected
eatures have a small contribution to the value of the scoring func-
ion. Backward elimination proceeds inversely and starts from the
ull feature set and eliminates features until a given scoring func-
ion reaches its maximum. An example of such an approach is the
educe Feature Elimination method that can be combined with a
lassiﬁer such as a Support Vector Machine [217]. Feature transfor-
ation methods construct new features from the original features
hile maintaining the initial data structure as accurately as possi-
le. Typical feature transformation methods create a supervised
r unsupervised mapping function that changes the initial fea-
ure space into a transformed variable space. The most widely
sed methods for feature transformation is principal component
nalysis (PCA), Fourier and the wavelet transformations. The most
opular feature transformationmethods coupled to statistical clas-
iﬁcation are Principal Component Linear Discriminant Analysis
ndPartial Least Square LinearDiscriminantAnalysis.Many featureing the relevance of the selected biomarkers by permutation tests (6). Panel (b)
gives an overview over the generic double cross validation strategy to measure the
performance of the feature selection-classiﬁer modules (modules 4–6).
Figures taken with reprint permission from Smit et al. [214].
selection methods are available and it is difﬁcult to predict, which
of them perform the best with respect to the others. Since many of
the features in biological samples are correlated, in context, collec-
tive feature selection and feature transformation methods taking
account of this correlation are preferable.
3.3. Classiﬁcation methods and statistical validation
Fig. 4 shows the main modules of statistical data analysis and
validation [214,216]. Feature selection and statistical analysis form
the core, which is surrounded by different stages of validation lay-
ers to ensure that the resulting classiﬁcation models are robust
with respect to new sample sets. From the core modules, only
the classiﬁcation module is compulsory while feature selection
and ultimately biomarker selection are optional if the classiﬁca-
tion method is not sensitive to HDSS and if sample classiﬁcation is
the only goal without identifying the underling molecular deter-
minants. The ﬁrst validation layer serves to select the optimal
classiﬁcation model (module 4) and the second layer measures
classiﬁer performance (module 5) by providing an error rate when
classifying new samples, which were not used for building and
selection of the classiﬁcation model. Finally the relevance of the
discrimination of themodel is determined by comparing its perfor-
mance to models obtained by chance using e.g. permutation tests
(module 6). Permutation tests randomly reassign sample group
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abels thus generating random models and the performance of a
arge number of randommodels is compared to the performance of
he model obtained with the correct sample labels [216]. Generally
alidation modules 4 and 5 are based on a double cross validation
trategy, with model selection occurring in the inner loop and clas-
iﬁcation performance being determined in the outer loop. Double
ross validation strategies provide an unbiased way of evaluat-
ng model selection criteria and classiﬁcation performance. This
s achieved by dividing samples in each group into a training set,
hich is used for model building, and a test set that is used for per-
ormance measurement in the inner and outer loops, respectively.
nother way to assess model performance is to determine the sen-
itivity and speciﬁcity of the statistical model by calculating the
o-called ROC curves [214,218]. Current developments in statisti-
al analysis focus on a combination of several methods resulting in
nsemble classiﬁers. The reader is referred to more comprehensive
eviews for details about feature reduction, dimensional reduction,
tatistical analysis and validation methods [146,216,219].
Most biomarker discovery studies are performed using sam-
les from different groups, which are obtained from different
ndividuals (e.g. patients or animals) not related to each other
cross-sectional study design). A study design where samples from
he same individual are analyzed at different time points (longi-
udinal study design) enables to lower the biological variability.
t is possible to further decrease the effect of biological variabil-
ty by matching the different clinical parameters such as age, sex,
moking habits or living style. In this case statistical analysis should
ake the relation between samples into account by using adapted
ethods (e.g. time series analysis) to correlate compound concen-ration to time or other parameters such as drug dosage or disease
evelopment status [220–223].
Quantitative peak matrices can be used for different purposes
han identifying class speciﬁc discriminating compounds. Fig. 5a
hows the histogram of the relative standard deviation (RSD) of the
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ig. 5. Histograms of the relative standard deviation (RSD) of compound concentration
ssessment of two LC–MS proﬁling platforms used for comparative proteomics studies
75m internal diameter) integrated in a microﬂuidic device and coupled to the mass
mm internal diameter reverse phase column coupled to the mass spectrometer via an e
he Chip-LC–MS (in blue) and the Cap-LC–MS (in red) platforms result in similar compoun
roﬁling platforms. In both cases 10 serum samples from the same patient were deplete
rocedures. These data thus contains only the analytical variability. Five injections of t
ndicating that most of the analytical variability is not caused by the Chip-LC–MS proﬁl
rypsin digestion). (b) Assessment and comparison of compound concentration variability
iomarker research projects. Twenty chromatograms of trypsin-digested human serum s
most abundant proteins give a narrower RSD histogram with respect to compound co
atient and subjected to an experimental design study (19 chromatograms) obtained by
rine samples result in the widest RSD distribution (red histogram), which may be explain
hus devoid of homeostatic control. (For interpretation of the references to color in this ﬁ
igures taken with reprint permission from Horvatovich et al. [99] and Christin et al. [95]3 (2011) 1209–1224
quantity of all compounds in a given dataset, where variability was
only subjected to analytical variance due to the use of two different
LC–MS analysis platforms. The histograms show that the two plat-
forms perform equally well to quantify peptides in serum samples
depleted of the six most abundant proteins [99]. The aligned peak
matrix also contains information about the global concentration
variability of compounds in the different datasets. This compar-
ison can be performed similarly using histograms of the RSD as
presented in Fig. 5b for three different types of sample sets [95].
The ﬁgure shows that there are large differences in concentration
variability between samples sets of different origin, such as acid-
precipitated urine, serumdepleted of the 6most abundant proteins
and a serum sample from one patient that was subjected to varied
pre-analytical factors in a factorial design study. While the com-
pounds of the ﬁrst two datasets were subjected to biological and
analytical variability in addition to errors during data processing,
compounds of the last dataset were only subjected to analytical
variability and data processing errors. The histograms indicate that
well regulated body ﬂuids, such as serum, show less concentration
variability than the same type of sample measured with differ-
ent preanalytical factors in a factorial design study. An excreted,
non-regulated body ﬂuid, such as urine, showed the largest con-
centration variability. Finally, quantitative peak matrices can be
used to evaluate and compare the quality of different data pro-
cessing pipelines using datasets containing compounds that were
added in known concentrations by spiking. Grossmann et al. [47]
compared the quantiﬁcation performance of two relative spectral
count methods (emPAI and APEX), absolution protein quantiﬁca-
tion method using the abundances of the three most abundant
peptides developed by Silva et al. [55] and four different protein
quantiﬁcationmethodsusingSuperhirn (MS1basedquantiﬁcation)
by assessing the robustness and dynamic range of the spiked-in
protein as well as non-altered proteins detected in the mixture of
spiked yeast samples. The protein quantiﬁcation method of Silva
0 50 100 150 200 250 300
0
200
400
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800
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Urine
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Relative Standard Deviation (%)
s calculated based on results of the corresponding quantitative peak matrices. (a)
. The Chip-LC–MS platform was equipped with a reverse phase nano-LC column
spectrometer via an electrospray interface, while the Cap-LC–MS platform used a
lectrospray interface using a nebulisation gas (ionspray). The histograms show that
d concentration variabilities and can thus be considered as equivalent quantitative
d of the 6 most abundant proteins and underwent individual sample preparation
he same sample in Chip-LC–MS (green) resulted in histograms with a lower RSD
ing platform itself but originates from the sample preparation steps (depletion or
after accurate data processing of different types of body ﬂuid analyses fromongoing
amples obtained from 10 different patients at two time points and depleted of the
ncentration (green histogram) than the same type of samples obtained from one
varying pre-analytical parameters (blue histogram). Fifty acid-precipitated human
ed by the fact that serum is a well-regulated body ﬂuid while urine is excreted and
gure legend, the reader is referred to the web version of the article.)
.
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t al. [55] with own implementation or using Superhirn [83] pro-
ided the best performance compared to emPAI or APEX methods,
owever their results should be taken carefully as they have used
ne bovine protein (Fetuin-A of 38.4 kDA) for spiking, which has
ery different composition (low homology) than that of the yeast
roteome. Another recent paper compared the quantiﬁcation per-
ormance of two commercial label-free LC–MS data processing
oftware (Eluciator and Progenesis) based on spiked samples, and
eported considerable differences in the performance [224].
. Conclusion and future trends
Improvement and development of new data processing
ipelines and individual modules will continue in the future as
ass spectrometry-based molecular proﬁling is gaining momen-
um in life science research and development of new mass
pectrometers and sample preparation methods is on the agenda
f numerous research groups and companies. In current bioinfor-
atics literature, there is increasing emphasis on the development
f algorithms which assess and compare the performance of data
rocessingmethods. Thesealgorithmsalsoprovide substantial sup-
ort for parameter optimization and troubleshooting of algorithms.
erformance assessment andquality control can be only performed
ith high quality standard data, where compound composition
nd quantity are precisely known [225]. To assess the perfor-
ance of protein identiﬁcation workﬂows, which report enhanced
erformance to detect known and unknown post translation mod-
ﬁcations, there is a need for open access well annotated MS/MS
ata [182]. Similarly, for assessing quantitative label-free data pro-
essing workﬂows, it is necessary to provide reference data from
ifferent biological origins such as urine, serum treatedwith differ-
nt depletion techniques or different cell lines spiked with known
ompounds in known concentrations. Development and access
o standardized samples such as the recently introduced yeast
tandard sample help this procedure [225]. Well-characterized
atasets also help to evaluate the performance of statistical anal-
sis and validation strategies. Raw and processed data simulation
oftware could, in certain circumstances, replace real datasets or
reate datasets with particular properties, which are difﬁcult to
btain experimentally, and which may reduce assessment time
onsiderably. For this reason, well characterized and documented
atasets stored in free access databases such as Human Proteinpe-
ia [226–228], and the development of accurate data simulation
ools will, in the future, enhance the comparison and accurate
erformance assessment of different modules or/and complete
ata processing workﬂows. An example of quality assessment and
arameter optimization of time alignment algorithms using well-
eﬁned samples is provided by Peters et al. in a recent publication
229].
Another trend is to develop data processing solutions to inte-
rate highly diverse data such as data obtained with different
nstruments or in different laboratories. An example of suchdiverse
ata, which cannot be processed with the actual data process-
ng pipelines, is presented in Fig. 6 showing a representation of
wo raw LC–MS datasets that were obtained form the same serum
ample with the same ion trap mass spectrometer, but using two
ifferent ionization methods and two different HPLC techniques.
hile the two samples contain exactly the same compounds at
he same concentration and have the same measured dynamic
oncentration range, the differences caused by the different chro-
atographic methods and the different ionization modes results
n different peak distributions in the retention time and m/z space.
urrent LC–MS data processing workﬂows are not able to accu-
ately combine these types of data sets, leaving this challenge for
uture developments.Fig. 6. LC–MS images of trypsin-digested human serum samples depleted of the
6 most abundant proteins obtained with the Chip-LC–MS (electrospray) (a) or the
Cap-LC–MS platform (ionspray) (b). See Horvatovich et al. [99] and the caption of
Fig. 5 for a description of the different LC–MS systems.
Newly developed or enhanced algorithms are emerging rapidly
within bioinformatics research groups. However these new algo-
rithms, with a high potential to ameliorate information extraction
accuracy fromrawdata andbiological knowledgediscovery, arenot
used by the majority of the data producing, application-oriented
proteomics laboratories. The main reason for the low penetration
of new bioinformatics solutions is that mass spectrometer ven-
dorsgenerallyprovideuser-friendlydataprocessingandevaluation
pipelines supported by training sessions favoring the application
of their own software packages, even if the performance of these
software packages is not assessed and compared with others. The
newly developed algorithms, even if the open source program code
is available, require on the other hand extensive bioinformatics
expertise, which is not present in most data producing proteomics
laboratories. In order to allow a breakthrough for the widespread
application of newly developed algorithms and software tools, it
is necessary to develop infrastructure programs, which provide
data processing services using integrated tools with access to high-
capacity, parallel computing facilities, such as large local clusters
or grid. Indeed biologists planning proteomics or in general life
science experiments to answer relevant biological questions may
workmore efﬁciently if they have to concentrate only on the exper-
imental design of the biological study, onproduction of highquality
data and interpretation of the obtained data using easy-to-use,
user friendly data processing services. To facilitate data interpre-
tation, the complexity of the software and hardware operations
should be hidden, and the end user should be only exposed to raw
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ata management, parameter setting of data processing and other
ioinformatics tools, to monitor the data processing status and to
isualize the processed data in a user-friendly way. An example
or such a framework software is Galaxy [230,231] or Genepattern
232,233], which is extensively used to analyze new generation
NA sequencing data. The framework should make the integration
f new bioinformatics tool easy and allow to modify complex data
rocessing workﬂows to adapt to the large diversity of mass spec-
rometers and sample preparation methods that generate highly
iverse data. A key element for the efﬁcient and easy integration
f diverse bioinformatics tools in such a software framework is to
se a standard format, which serves to interconnect the input and
utput ﬁles of the integrated tools.
Attempts have been made in the ﬁeld of proteomics with the
ramework program CORRA [234], which integrates the SuperHirn
83] and SpecArray [86] label-free quantitative data processing
ipelines, and includes MS/MS identiﬁcation based on Sequest
150] with a range of R-based statistical tools. CORRA uses the
nnotated Putative peptide Markup Language (APML) format to
ntegrate the different modules of the quantitative data processing
ipelineswith protein identiﬁcation and statistical analysis. CORRA
rovides a user-friendly web interface and executes the different
rocessing tasks on a local cluster. However CORRA cannotmanage
arge amounts of diverse metadata, as needed for effective project
anagement, and the integrated tools are limited to bioinformat-
cs modules developed in a closely collaborating bioinformatics
ommunity. Developing further CORRA and APML or other similar
nitiatives shouldprovide abreakthrough inusingnewlydeveloped
ioinformatics tools and therefore accelerate life science research.
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